360 Stem Cell & Regenerative Medicine Newsletter- June 25, 2015

 weSRCH's Best of the Internet Award

Share: FacebookTwitterLinkedInGoogle

360 Stem Cell & Regenerative Medicine Newsletter - June 25, 2015

Featured Video from Stanford Medicine: The Butterfly Effect- Skin Too Fragile to Touch

This is an incredibly moving 6-minute video describing the plight of patients suffering from a devastating affliction- a blistering skin disease called epidermolysis bullosa. Can stem cell researchers find an answer and end the suffering? Read the entire article here.

World Stem Cell Summit

RMF/GPI: World Stem Cell Summit & RegMed Capital Conference Weekly Update
Special pre-early bird pricing ends in July for the 11th World Stem Cell Summit and the RegMed Capital Conference at the Hyatt Regency Atlanta (USA) December 10-13.

Newly confirmed speakers include:

Chris Mason, MBBS, PhD, FRCS, Professor of Regenerative Medicine Bioprocessing in the Advanced Centre for Biochemical Engineering, University College London is working on the clinical translation and commercialization of cell and gene therapies, and tissue-engineered products. Dr. Mason has a multidisciplinary track record, spanning therapeutics, medical devices and information technology, in discovery, clinical medicine, bioprocessing, regulation, healthcare economics, reimbursement and business.

Jane C. Andrews, PhD, Senior Consultant, Healthcare and Life Sciences, Frost & Sullivan. She is the multidisciplinary project leader in the life sciences including regenerative medicine, In Vitro diagnostics, medical devices; alternative animal models; pharmaceuticals, animal health, and business development & evaluation.

S. Peter Ludwig is a principal in the New York office of Fish & Richardson, a preeminent law firm specializing in intellectual property. Mr. Ludwig’s practice is focused on domestic and foreign patent prosecution, litigation, interference and counseling issues, particularly in representing start-up companies and academic institutions. His technical expertise includes biotechnology (vaccines, functional genomics, stem cells, pharmacogenomics, high throughput screening, stem cell technology, autoimmune diseases, gene therapy), pharmaceuticals (neuroleptic drugs, drug delivery systems, anti-metabolites, natural pharmaceuticals, anti-tumor agents, anti-viral agents), medical devices, and diagnostic products.

Welcome to the Sanford Burnham Prebys Medical Discovery Institute! A $100 Million Gift and a New Name
“Sanford-Burnham has received a gift of $100 million from prominent San Diego developer, philanthropist, and Sanford-Burnham honorary trustee Conrad Prebys. The gift will be used to further implement the Institute’s 10-year strategic vision to accelerate the delivery of innovative new treatments that will have a tangible impact on improving human health. In recognition of Prebys’ contribution, Sanford-Burnham Medical Research Institute will now bear his name, along with the other Institute namesakes T. Denny Sanford and Malin Burnham. Effective June 24, the new name will be Sanford Burnham Prebys Medical Discovery Institute.”

360 Note: The Sanford- Burnham Medical Research Institute is a major hub for advanced stem cell research.

Wake Forest

Ontario Ministry of Information: Province Invests $25 Million in Stem Cell Research Funding the Ontario Institute for Regenerative Medicine to Study Chronic Disease Treatments
“Ontario is investing $25 million over five years to support new treatments and therapies for people living with chronic diseases, such as cancer, multiple sclerosis and diabetes.”


NHLBI Next Gen Consortium Partners with WiCell to Distribute Over 1,500 Well-Characterized, Novel Cell Lines for use in Disease Research
“The National Heart, Lung, and Blood Institute (NHLBI) Next Gen Consortium has designated WiCell to serve as the repository and distributor of the cell lines. Upon receipt from the depositing institutions, WiCell will make the cell lines available to researchers. Genotype, phenotype and clinical data available for the donors of each cell line will be available through the NIH National Center for Biotechnology Information’s dbGAP and linked to each cell line on the WiCell website to aid researchers in making cell line decisions.”

Vice News: The Canadian Military Wants to Use Stem Cells to Help Its Soldiers Heal
“It has experimented with Arctic drones, designed the next generation of smart rifles and developed secure wifi networks for combat platoons. Now, the Canadian Armed Forces is looking to develop a battlefield-ready adult stem cell program to help its soldiers quickly heal devastating wounds. Scientists at Defense Research and Development Canada (DRDC) are developing a project that aims to create potential tools for rapid healing and protection against chemical warfare agents.”


San Jose Mercury News: Stanford Stem Cell Product, Delayed for More Than a Decade, to be Tested Again
“In the 1990s, Stanford's Irv Weissman created a unique way to grow and deliver blood stem cells to desperate patients with aggressive cancers, boosting survival rates. But then the discovery itself died -- a victim of the heartbreaking economics of commercial stem-cell development, where the long and rocky road of research, especially in the field of ‘personalized medicine,’ often discourages investment. Now, 10 years after the technique's sale and then abandonment by a biotech company, it is back in Weissman's hands. The goal, he said, is to finally resume his research to prove, once and for all, its effectiveness in patients with no other hope.”

360 Note: This is an interesting story and a lesson for researchers to be careful what they wish for-too rapid commercialization of promising research might actually delay medical breakthroughs.

University of Virginia Health System: Diabetic blindness: UVA IDs Best Source of Stem Cells to Battle Vision Loss
“UVA School of Medicine researchers have taken a significant step forward in their efforts to use stem cells to block vision loss caused by diabetic retinopathy, a condition that affects millions of people with diabetes. The researchers have evaluated the best potential sources for adult stem cells to be used for that purpose, determining that cells taken from donors who do not suffer diabetes likely will be more effective than cells taken from patients’ own bodies. The work is a critical step toward the goal of injecting stem cells into patients’ eyes to stop or even reverse the vision loss. The findings also establish a crucial framework for evaluating stem cells to be used in potential future treatments for diabetic retinopathy.” The findings were published in the official journal of the Regenerative Medicine Foundation, Stem Cells Translational Medicine.


HealthCanal: Specific Roles of Adult Neural Stem Cells May Be Determined Before Birth
“Adult neural stem cells, which are commonly thought of as having the ability to develop into many type of brain cells, are in reality pre-programmed before birth to make very specific types of neurons, at least in mice, according to a study led by UC San Francisco researchers.” The study was published in Cell.

HealthCanal; UCSF Scientists Identify Progenitor Cells for Blood and Immune System- Aim for Better Balance of Cell Populations to Combat Aging and Cancer
“UC San Francisco scientists have identified characteristics of a family of daughter cells, called MPPs, which are the first to arise from stem cells within bone marrow that generate the entire blood system. The researchers said the discovery raises the possibility that, by manipulating the fates of MPPs or parent stem cells, medical researchers could one day help overcome imbalances and deficiencies that can arise in the blood system due to aging or in patients with specific types of leukemia.”

Wake Forest

Press Release: Fluidigm Revolutionizes In Vitro Modeling for Stem Cell Researchers and Cell Biologists
In a company press release, Fluidigm Corporation announced its CallistoTM system, a fully automated and programmable microfluidic cell culture system that integrates multifactorial dosing in 32 individual chambers for simultaneous cell culture. This innovative new platform will revolutionize the way cell biologists develop in vitro cell models. “By providing multifactorial dosing, transfection, and precise environmental control of cells in a microfluidic environment, Callistois the first platform to enable stem cell and other cell researchers to design, optimize, and execute complex cell culture protocols, such as cellular reprogramming, differentiation, characterization, and dose response studies. With just a few touches on a computer screen, biologists will be able to study and analyze the developmental stages and behavior of living cells, such as induced pluripotent stem cells (iPS cells), embryonic stem cells, and other cell types, in their microenvironment over the course of several weeks.”

360 Newsletter Editor

Bernard Siegel
Executive Director
Genetics Policy Institute

Stem Cells and the Transformative Power of Hope-a TEDx talk by Bernard Siegel, Editor of 360 Newsletter

About GPI

The nonprofit Genetics Policy Institute (GPI) seeks to establish a positive policy, regulatory and societal framework to enable research to flourish, under the highest ethical and medical standards. We seek to accelerate the discovery and development of lifesaving cures and therapies to alleviate human suffering due to chronic and terminal afflictions. Visit Website.

ConnectGPI on FacebookGPI on TwitterGPI on LinkedIn

Genetics Policy Institute (GPI) and the Regenerative Medicine Foundation (RMF) Announce Merger Plan

Domain: Medical
Category: Biology

Recent Newsletters

12 March, 2019
10 October, 2018
15 February, 2018